Ontario becomes the first province to publicly reimburse the first targeted oral therapy for adults with Grade 2 IDH-mutant glioma.

VORANIGO (R) was approved by Health Canada in August 2024 for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation in adults and pediatric patients aged ...

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma

If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or ...